Sat, Jan 31, 2015, 5:14 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Galectin Therapeutics, Inc. Message Board

  • biotuesday biotuesday Aug 20, 2013 8:23 AM Flag

    BioTuesdays: Galectin targets silent epidemic in liver fibrosis

    Fatty liver disease, or the accumulation of fat in liver cells, is a “silent epidemic,” says Dr. Peter Traber, president, CEO and chief medical officer of Galectin Therapeutics (NASDAQ:GALT).

    In an interview with BioTuesdays, he says multiple liver diseases lead to fibrosis, and end-stage fibrosis, or cirrhosis, leads to liver failure, medical complications and death. “With fatty liver disease, the most common liver disease, there are very few symptoms until patients reach late-stage disease, with advanced fibrosis and then cirrhosis.”

    There is no approved medical therapy for liver fibrosis, and the only current therapy is a liver transplant. Dr. Traber points out that fatty liver disease with fibrosis, or non-alcoholic steatohepatitis (NASH), has a prevalence of nine-to-15 million people in the U.S., of which 25% to 30% will develop cirrhosis. Dr. Traber further points out that NASH cirrhosis is projected to be the No. 1 reason for a liver transplant.

    See BioTuesdays for rest of article......

3.22-0.23(-6.67%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.